GPCR — Structure Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1888886 ·
Last close
$18.17
Market Cap
$1.30B
52W High
$94.90
52W Low
$17.81
ADV30
1,051,534
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -156,333,000 | -144,757,000 | 1,334,419,000 | 222,033,000 | 112,549,000 |
| Jun 2026 | 0 | — | -118,630,000 | -106,159,000 | 1,425,415,000 | 272,638,000 | 71,011,000 |
| Mar 2026 | 0 | — | -89,379,000 | -75,968,000 | 1,508,124,000 | 316,168,000 | 61,030,000 |
| Dec 2025 | 0 | — | 13,740,000 | 33,004,000 | 1,583,918,000 | 799,623,000 | 67,541,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-270,997,000
Investing CF
$-315,946,000
Financing CF
$706,064,000
CapEx
$-7,895,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.03
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-797,184,000
Inventory
—
Receivables
$0
ST Investments
$1,017,942,000
EBIT TTM
$-350,602,000
Pretax Income TTM
$-293,115,000
Interest Exp TTM
—
Analysts
14
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -186,809,000 | -141,202,000 | 1,583,918,000 | 67,541,000 | 1,516,377,000 | -222,199,000 |
| Dec 2024 | 0 | -158,228,000 | -122,526,000 | 903,330,000 | 38,487,000 | 864,843,000 | -116,636,000 |
| Dec 2023 | 0 | -102,775,000 | -89,620,000 | 482,017,000 | 29,051,000 | 452,966,000 | -79,488,000 |
| Dec 2022 | 0 | -52,561,000 | -51,321,000 | 97,845,000 | 212,985,000 | -115,140,000 | -46,120,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-214,835,000
OpCashFlow TTM
—
Assets (Latest)
$1,425,415,000
Forward EPS
$-2.50
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| INVA | Innoviva, Inc. | $1.30B | $18.30 | — |
| LBRX | LB PHARMACEUTICALS INC | $1.30B | $40.30 | — |
| MNKD | MANNKIND CORP | $1.31B | $4.07 | — |
| MLYS | Mineralys Therapeutics, Inc. | $1.28B | $14.48 | — |
| OCUL | OCULAR THERAPEUTIX, INC | $1.32B | $6.02 | — |
News headlines (Yahoo Finance, 1h cache)
Structure Therapeutics (GPCR) Posts Wider Losses, Is The Discount Too Deep?
2026-11-16 23:20 · Yahoo
Unlearn and Structure Therapeutics Collaborate to Apply AI-Generated Digital Twins in Obesity Research
2026-11-12 12:00 · Yahoo
Structure Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
2026-11-09 21:05 · Yahoo
Raised Guidance Could Change The Case For Schrödinger Stock (SDGR)
2026-11-07 20:12 · Yahoo
Structure Therapeutics to Participate in the Jefferies Global Healthcare Conference
2026-11-04 12:30 · Yahoo
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026
2026-10-19 20:13 · Yahoo
Structure Therapeutics (GPCR) Stock May Be A Bargain Given Its Asset Base
2026-10-17 03:23 · Yahoo
What Schrodinger (SDGR) Said on Its Q3 Earnings Call
2026-11-05 04:14 · Yahoo
4 Key Stocks to Watch Across Diabetes and Obesity This Awareness Day
2026-11-13 13:13 · Yahoo
Will Wegovy Pill Drive Renewed GLP-1 Growth Momentum for Novo Stock?
2026-11-11 15:56 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.